

Results

Pre- And Post-Treatment: Patient Treated With Dupilumab 300 mg Weekly

Baseline:

- IGA score: 4
- BSA affected: 86.5%
- EASI score: 51.5
- Pruritus NRS: 7
- AD duration: 48 years



Week 16



Week 16:

- IGA score: 1
- BSA affected: 2.5%
- EASI score: 3.1
- Pruritus NRS: 1.6

Example of a patient who achieved IGA 1 in the clinical trial and is not representative of all patients. Individual results did vary. Photo used with permission.

IGA, Investigator Global Assessment; BSA, Body Surface Area; EASI, Eczema Area and Severity Index; NRS, Numerical Rating Scale.

Clinical Update: Dupilumab

Beck et al. *N Engl J Med*. 2014 Jul 10;371(2):130-9